News IDEAYA/Servier PKC drug aces uveal melanoma trial Servier $210m bet on IDEAYA's uveal melanoma therapy darovasertib seems to have paid off, as a trial sets up regulatory filings later in 2026.
News AI could spare bowel cancer patients from unneeded treatment An AI tool could identify colorectal cancer patients most likely to respond to bevacizumab, which was recently backed for NHS use.
News Data backs GSK's ovarian cancer blockbuster hopes GSK's B7-H4-targeting ADC Mo-Rez chalks up impressive results in ovarian and endometrial cancer, prompting a major phase 3 trials programme.
News FDA hands another rejection to Replimune's melanoma therapy Replimune has had its advanced melanoma treatment RP1 turned down by the FDA for a second time, prompting job losses.
News Roche places a $1bn bet on C4T degrader-antibody conjugates Roche is paying $20 million upfront to secure rights to two degrader-antibody conjugates (DACs) for cancer developed by longtime partner C4T.
Oncology From preclinical toxicology to clinical safety: The path for... Successfully navigating the process for drugs with a higher risk-benefit ratio requires a tailored non-clinical programme design.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.